Archived Medical News Stories

<< Back to Main Archives Index

RSSArchived Drug Trial News Stories - April 2010

Date Title Comments Rating
2010-04-30 GeNOsys sponsors Phase I safety trial in collaboration with Nitric Solutions 0 None
2010-04-30 Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound 0 None
2010-04-30 Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis 0 None
2010-04-30 Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder 0 None
2010-04-30 Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex 0 None
2010-04-30 Novavax reports positive results from Phase II study of trivalent VLP influenza vaccine in older adults 0 None
2010-04-30 TenX Biopharma signs Clinical Trial Agreement with NCI 0 None
2010-04-30 Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials 0 None
2010-04-30 EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout 0 None
2010-04-30 Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan 0 None
2010-04-30 Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC 0 None
2010-04-29 Celgene's first-quarter non-GAAP total revenue up 31% to $789 million 0 None
2010-04-29 Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma 0 None
2010-04-29 Human Genome Sciences reports net loss of $47.9M for first-quarter 2010 0 None
2010-04-29 AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010 0 None
2010-04-29 Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment 0 None
2010-04-29 Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI 0 None
2010-04-29 Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting 0 None
2010-04-29 CINJ trial targets new combination therapy for advanced solid tumors 0 None
2010-04-29 Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010 0 None
2010-04-29 Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics 0 None
2010-04-29 Geron reports net loss of $16.6M for first-quarter 2010 0 None
2010-04-29 Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis 0 5
2010-04-29 Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients 0 None
2010-04-29 Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint 0 None
2010-04-29 Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease 0 None
2010-04-29 Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated 0 None
2010-04-28 Positive results from interim analysis of ongoing Phase 2a study of BCX4208 0 None
2010-04-28 Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch 0 None
2010-04-28 BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine 0 None
2010-04-28 Seattle Genetics reports revenues of $46.5M for first-quarter 2010 0 None
2010-04-28 Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010 0 None
2010-04-28 Update on ICA-105665 clinical development plans for treatment of epilepsy and pain 0 None
2010-04-28 ChronSeal multi-center study in Sweden and Norway finalized 0 None
2010-04-28 DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients 0 None
2010-04-28 NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer 0 None
2010-04-28 Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010 0 None
2010-04-28 Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets 0 None
2010-04-28 Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress 0 None
2010-04-27 Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor 0 None
2010-04-27 Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS 0 None
2010-04-27 Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI 0 None
2010-04-27 ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE 0 None
2010-04-27 Prime-boost malaria vaccine regimen provides sterile protection: Vical 0 5
2010-04-27 UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV 0 None
2010-04-27 LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand 0 None
2010-04-27 Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme 0 None
2010-04-27 Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting 0 None
2010-04-27 Phase 2b clinical study initiated to evaluate GI safety of LT-NS001 0 None
2010-04-27 FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco 0 None
2010-04-26 OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva 0 None
2010-04-26 First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD 0 None
2010-04-26 Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer 0 None
2010-04-26 Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting 0 None
2010-04-24 Recent business progress at Penwest Pharmaceuticals 0 None
2010-04-24 Study finds AFREZZA comparable to standard of care insulin therapy 0 None
2010-04-24 Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study 0 None
2010-04-24 Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program 0 None
2010-04-24 AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing 0 None
2010-04-23 Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas 0 None
2010-04-23 Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010 0 1
2010-04-23 Affymax institutes quiet period in connection with Hematide Phase 3 result analysis 0 None
2010-04-23 Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor 0 None
2010-04-23 Gelesis presents Attiva data at AACE 19th Annual Meeting & Clinical Congress 0 None
2010-04-23 Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research 0 None
2010-04-23 Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting 0 5
2010-04-23 Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation 0 None
2010-04-23 Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC 0 None
2010-04-23 Aragon Pharmaceuticals raises $22M through Series B financing 0 None
2010-04-22 Karo Bio reports net loss of MSEK 40.5 for January–March 2010 0 None
2010-04-22 Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated 0 None
2010-04-22 Vical presents Phase 2 trial results of TransVax CMV vaccine at World Vaccine Congress 0 None
2010-04-22 Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth 0 None
2010-04-22 Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium 2 None
2010-04-22 Positive results from preclinical EP-302 program presented at AACR 2010 0 None
2010-04-22 AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR 0 None
2010-04-22 PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting 1 None
2010-04-22 ImmunoCellular Therapeutics, UPENN sign research agreement 0 None
2010-04-22 Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting 0 None
2010-04-22 Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR 0 None
2010-04-22 NO-naproxen blocks molecular changes leading to colorectal cancer development 0 None
2010-04-22 Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients 0 None
2010-04-22 Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer 0 None
2010-04-22 Delcath Systems' trial meets primary endpoint of extended hPFS in patients with melanoma metastases 0 None
2010-04-21 Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs 0 None
2010-04-21 HemaQuest Pharmaceuticals closes $12M Series B financing 0 None
2010-04-21 Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing 0 None
2010-04-21 Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously 0 None
2010-04-21 Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010 0 None
2010-04-21 Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010 0 None
2010-04-21 Initial results of gallium-containing compound to treat serious infection presented at AACR 2010 0 5
2010-04-21 ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting 0 None
2010-04-21 Preclinical data in neuroblastoma for perifosine to be presented at AACR 2010 Meeting 0 None
2010-04-21 Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies 0 None
2010-04-21 Roche's progress of RG7348 into Phase I clinical trial triggers $6.5M milestone payment to Ligand 0 None
2010-04-21 Lotus Pharmaceuticals' asthma drug Laevo-Bambutero to receive Chinese SFDA Fast Track Approval 0 None
2010-04-21 Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress 0 None
2010-04-21 IMPACT trial shows improvement in OS for metastatic CRPC 0 None
2010-04-21 Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells 0 None
2010-04-21 Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS 0 None
2010-04-20 Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus 0 None
2010-04-20 NeoPharm commences enrollment in Phase II clinical trial of LE-DT for pancreatic cancer 0 None
2010-04-20 Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients 0 None
2010-04-20 Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010 0 None
2010-04-20 Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting 0 None
2010-04-20 Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis 0 None
2010-04-20 NanoBio to develop intranasal vaccine for HBV 0 None
2010-04-20 Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy 0 None
2010-04-20 XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels 0 None
2010-04-20 Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR 0 None
2010-04-20 On-going phase II trial of octagam in AD to be discussed at ICAD 2010 0 None
2010-04-20 Statin use may increase risk of developing benign colorectal tumors: APC trial 0 None
2010-04-20 ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint 0 None
2010-04-20 Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy 0 None
2010-04-20 Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies 0 None
2010-04-20 Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C 0 None
2010-04-19 Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer 0 None
2010-04-19 Raloxifene, tamoxifen remain effective options in prevention of breast cancer, finds 19,490-patient study 0 None
2010-04-19 Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010 0 None
2010-04-19 Jennerex presents positive interim data from Phase 2 clinical trial of JX-594 for HCC at 45th EASL 0 None
2010-04-19 Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals 0 None
2010-04-19 Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood 0 None
2010-04-19 Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010 0 None
2010-04-19 Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC 0 4
2010-04-19 Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus 0 None
2010-04-19 Stallergenes' US phase III clinical trial of Oralair achieves primary endpoint 0 5
2010-04-19 Amgen announces results from pivotal Phase 3 "408" trial of Vectibix 0 None
2010-04-19 Results of BATTLE Trial presented at AACR 2010 0 None
2010-04-19 Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress 0 None
2010-04-17 G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks 0 None
2010-04-17 Ocera Therapeutics presents data on prevalence of neurocognitive impairment in cirrhotic patients 0 None
2010-04-17 Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH 0 None
2010-04-17 New data on Cladribine Tablets presented at AAN annual meeting 0 None
2010-04-17 Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009 0 None
2010-04-17 Knopp Neurosciences to initiate Phase 3 studies of KNS-760704 in AL 0 3.7
2010-04-17 RegeneRx Biopharmaceuticals proposes common stock public offering 0 None
2010-04-16 Repligen expects total revenue of $21.0M for fiscal year 2010 0 None
2010-04-16 VisEn Medical expands FMT imaging platform 0 None
2010-04-16 Results of study comparing REMICADE to azathioprine for Crohn's disease published 0 None
2010-04-16 InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL 0 None
2010-04-16 Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment 0 None
2010-04-16 Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV 0 None
2010-04-16 Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting 0 None
2010-04-16 Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL 0 None
2010-04-16 Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial 0 None
2010-04-16 Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate 0 None
2010-04-16 Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting 0 None
2010-04-16 Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting 0 5
2010-04-16 LOTS results of Myozyme in older children and adults with Pompe disease published 0 None
2010-04-16 Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies 0 None
2010-04-16 Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066 0 None
2010-04-16 Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222 0 None
2010-04-16 Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN 0 None
2010-04-15 Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422 0 None
2010-04-15 Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting 0 None
2010-04-15 Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine 0 None
2010-04-15 AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting 0 1
2010-04-15 Investment report on MIPI 0 None
2010-04-15 Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting 0 None
2010-04-15 Interim results from Pharmasset's phase 2a combination study of PSI-7977 with Pegasys and Copegus for HCV 0 None
2010-04-15 Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting 0 None
2010-04-15 Phase I clinical trial of DFMO initiated to treat children with neuroblastoma 0 None
2010-04-15 Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients 0 None
2010-04-15 Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights 0 None
2010-04-15 Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients 1 None
2010-04-15 Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting 0 None
2010-04-15 Kenta Biotech presents positive Phase IIa results of panobacumab 0 None
2010-04-15 Targeted therapy MDV3100 is effective for patients with CRPC: Study 0 None
2010-04-15 Opexa Therapeutics presents key efficacy data on Tovaxin 0 None
2010-04-15 Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD 0 None
2010-04-15 Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction 0 None
2010-04-15 Phase IIa clinical trial results of Serdaxin for treatment of MDD 0 None
2010-04-15 Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced 0 None
2010-04-15 ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals 0 None
2010-04-15 Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors 0 None
2010-04-15 First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial 0 None
2010-04-15 Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure 0 None
2010-04-13 EntreMed commences Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer 0 None
2010-04-13 Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting 0 None
2010-04-13 VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings 0 None
2010-04-13 Investment report on Rexahn Pharmaceuticals 0 None
2010-04-13 NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS 0 None
2010-04-13 Gilead Sciences doses first patient in Quad Phase III clinical program 0 None
2010-04-12 Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting 0 None
2010-04-12 XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting 0 None
2010-04-12 Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID 0 None
2010-04-12 Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles 0 None
2010-04-12 Results of Phase I ThermoDox dose escalation trial to be discussed in a press conference 0 None
2010-04-12 Clinical and preclinical malaria vaccine data presented at Keystone Symposium 0 None
2010-04-12 Phase I study of Affinium Pharmaceuticals' AFN-1252 for MRSA initiated 0 None
2010-04-12 Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin 0 None
2010-04-09 Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference 0 None
2010-04-09 Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting 0 None
2010-04-09 ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor 0 None
2010-04-09 Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting 0 None
2010-04-09 Combination telaprevir treatment beneficial for retreatment of hepatitis C 0 None
2010-04-09 Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis 0 None
2010-04-09 Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease 0 5
2010-04-09 Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine 0 None
2010-04-09 University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma 0 None
2010-04-09 Æterna Zentaris commences perifosine Phase 3 registration trial 0 None
2010-04-09 ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer 0 None
2010-04-08 Cubist Pharmaceuticals initiates dosing in Phase 2 trial with CB-183,315 for diarrhea due to CDAD 0 None
2010-04-08 Phase 1 SAD study of PSI-938 for HCV initiated 0 5
2010-04-08 OncoGenex Pharmaceuticals recognized with BIOTECanada's Gold Leaf Award 0 None
2010-04-08 Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine 0 None
2010-04-08 Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection 0 None
2010-04-08 Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated 0 None
2010-04-08 Results of M118 EMINENCE clinical trial published in Circulation 0 None
2010-04-08 Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme 0 None
2010-04-08 Encouraging results from OptiNose's sumatriptan Phase II study for migraine 0 None
2010-04-08 MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE 0 None
2010-04-08 Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18 0 None
2010-04-07 King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain 0 1
2010-04-07 Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda 0 None
2010-04-07 Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer 0 4
2010-04-07 MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting 0 None
2010-04-07 Nile Therapeutics to fund ongoing Phase II clinical trial of CD-NP with proposed public offering 0 None
2010-04-07 Nationwide Phase III clinical trial of OncoVEX for advanced melanoma 0 None
2010-04-07 Optimer Pharmaceuticals to present data from fidaxomicin Phase 3 studies at 20th ECCMID 0 None
2010-04-07 MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone 0 None
2010-04-06 Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting 0 None
2010-04-05 Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation 0 None
2010-04-05 Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD 0 None
2010-04-05 Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing 0 None
2010-04-05 Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure 0 None
2010-04-05 Spectrum Pharmaceuticals reports $15.7M revenue from ZEVALIN sales in 2009 0 None
2010-04-03 Clinical utility and pharmacological action of MN-166 in treatment of MS 0 None
2010-04-03 CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer 0 None
2010-04-02 Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate 0 None
2010-04-01 Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development 0 5
2010-04-01 Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment 0 None
2010-04-01 BELLUS Health initiates Phase I clinical study for NRM8499 0 None
2010-04-01 Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US 0 3
2010-04-01 Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study 0 None
2010-04-01 Positive results from Phase 2 clinical trial of OMS103HP 0 None
2010-04-01 Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout 0 None

Total

237 posts
4 comments
21 raters